| Trial Information | |
|---|---|
| Disease | Breast cancer and advanced endometrial carcinoma |
| Stage of disease/treatment | Recurrent/refractory metastatic |
| Prior therapy | Cohort 1: >2 prior lines of hormonal therapy Cohort 2/3: ≥1 line of chemotherapy for metastatic/recurrent disease |
| Type of study | Phase II, single arm in 3 cohorts. Cohort1: HR-positive breast cancer, Cohort 2: TNBC, Cohort3: endometrial cancer |
| Primary endpoint | Cohort 1: PFS Cohort 2/3: ORR |
| Secondary endpoints | Cohort 1: ORR, CBR, safety Cohort 2/3: PFS, CBR, safety |
| Investigator’s analysis | Level of activity did not meet planned endpoint. No evidence of effect on correlative endpoints. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.